Adjuvant trastuzumab promising but costly for breast cancer

Author：

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.500, 2006-01, pp. : 3-3

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Neoadjuvant trastuzumab promising in breast cancer

Inpharma, Vol. 1, Iss. 1484, 2005-01 ,pp. : 18-18

Adis International

Access to resources Recommend Favorite

Cost Effectiveness of Trastuzumab in the Adjuvant Treatment of Early Breast Cancer: A Lifetime Model

By Millar J. Alasdair Millward Michael J.

PharmacoEconomics, Vol. 25, Iss. 5, 2007-01 ,pp. : 429-442

Adis International

Access to resources Recommend Favorite

The cost-effectiveness issue of adjuvant trastuzumab in early breast cancer

By Norum Jan

Expert Opinion on Pharmacotherapy, Vol. 7, Iss. 12, 2006-08 ,pp. : 1617-1625

Informa Healthcare

Access to resources Recommend Favorite

Adjuvant trastuzumab for breast cancer that overexpresses HER2?

Inpharma, Vol. 1, Iss. 1280, 2001-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite

Adjuvant Trastuzumab for Breast Cancer: Uncertainties in Clinical and Economic Evidence Following Early Stopping of the HERA Trial

By Younis Tallal Skedgel Chris

PharmacoEconomics, Vol. 29, Iss. 5, 2011-05 ,pp. : 361-365

Adis International

Access to resources Recommend Favorite